Treatment options for Enterococcus faecalis bloodstream infection
Official title: Impact on Mortality of the Choice Between a Mono- Versus Combination Antibiotic Therapy in Enterococcus Faecalis Bacteremia
Run by University Hospital, Strasbourg, France · NCT07299539 · Data updated 2026-11-12
This project tests whether single-drug penicillin-based treatment or combination antibiotic therapy leads to better survival for adults with Enterococcus faecalis bloodstream infections.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 700 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | February 24, 2024 |
| Main results expected | December 2025 |
| Study ends | December 2025 |
| Registry record updated | December 23, 2025 |
| Trial ID | NCT07299539 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with a blood culture positive for Enterococcus faecalis diagnosed and treated at the University Hospital of Strasbourg who did not have endocarditis at diagnosis and received a penicillin-based regimen for at least seven days.
✕Probably not a fit
People with penicillin-resistant E. faecalis, polymicrobial bacteremia, infective endocarditis at diagnosis, or who died within 72 hours of starting antibiotics were excluded and would not benefit from the study's direct conclusions.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a retrospective observational analysis of adults with microbiology-confirmed Enterococcus faecalis bacteremia diagnosed at the University Hospital of Strasbourg from 2017 to 2023. The work compares outcomes in patients treated with bacteriostatic monotherapy versus bactericidal penicillin-containing combination regimens. Primary outcomes include mortality up to three months, and secondary outcomes include treatment failure, renal toxicity, and development of bacterial resistance. Patients with endocarditis at diagnosis, polymicrobial bacteremia, penicillin-resistant isolates, or very early death were excluded to focus on 'simple' E. faecalis bacteremia managed with penicillin-based therapy.
Why it matters
Potential benefit: If findings show one approach leads to lower mortality or fewer harms, they could guide clearer treatment choices and improve survival for people with this infection.
How similar studies have gone: Direct head-to-head comparisons for simple E. faecalis bacteremia are limited, with most existing data focusing on complicated infections or extrapolated from other contexts rather than clear evidence for single versus combination therapy.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject of legal age (≥18 years) * Having a positive blood culture result for Enterococcus faecalis identified within the microbiology laboratory of the University Hospital of Strasbourg during the period from 01 January 2017 to 31 December 2023. Exclusion Criteria: * Penicillin treatment \< 7 days * Treatment not containing a penicillin effective against enterococci among those studied: amoxicillin or piperacillin-tazobactam * Combination of penicillin with another antibiotic effective against enterococci other than cephalosporins or aminoglycosides (glycopeptides, linezolids, carbapenems, levofloxacin, moxifloxacin). * Bacteremia with one or more other pathogens within the first 7 days of bacteremia * Infective endocarditis at diagnosis and within the first 7 effective days of treatment * Resistance of Enterococcus faecalis to amoxicillin * Mortality \<72 hours after initiation of antibiotic therapy * Lack of information regarding the chosen antibiotic treatment
Where it's running
-
Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
Strasbourg, France Recruiting
Study contacts
- Study coordinator: Yvon RUCH, MD
- Email: yvon.ruch@chru-strasbourg.fr
- Phone: 33 3 69 55 12 1
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Patient-specific biomechanical modeling of incisional hernias with AI and finite element analysis
Researchers will test a personalized computer model of the abdominal wall for adults with incisional hernias using anonymized CT data and AI to see how the hernia shapes relate to tissue mechanics.
-
Menin inhibitors in pediatric relapsed or refractory acute leukemia
This study looks at kids with relapsed or treatment-resistant acute leukemia who have specific genetic changes and are treated with menin inhibitors to see how they fare.
-
Long-Term Epilepsy Outcomes in Children After Perinatal Stroke
This study looks at how epilepsy progresses in kids who had a stroke before 28 days old to see how their seizures and syndromes evolve over time.
-
Predictors of Success and Failure of v-NOTES Hysterectomy for Large Uteri
This study looks at which factors predict whether a v-NOTES hysterectomy for large uteri will be completed without needing to switch to another surgical approach.
-
Prehospital end-of-life care: how professionals use a comfort care booklet in Strasbourg
This study tests how emergency crew members in Strasbourg use a comfort care booklet when caring for patients at end of life, and what they think about it.
-
Toxicity of intensive first-line treatment for adult Burkitt lymphoma
This study looks back at adult Burkitt lymphoma patients treated with very aggressive first-line chemotherapy to see how toxic the treatment is and what their long-term outcomes were.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.